Logo image of LIMN

LIMINATUS PHARMA INC-CL A (LIMN) Stock Fundamental Analysis

NASDAQ:LIMN - Nasdaq - Common Stock - Currency: USD

8.47  +2 (+30.91%)

After market: 8.85 +0.38 (+4.49%)

Fundamental Rating

0

Taking everything into account, LIMN scores 0 out of 10 in our fundamental rating. LIMN was compared to 556 industry peers in the Biotechnology industry. Both the profitability and financial health of LIMN have multiple concerns. LIMN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LIMN had negative earnings in the past year.
In the past year LIMN has reported a negative cash flow from operations.
LIMN Yearly Net Income VS EBIT VS OCF VS FCFLIMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 2M -2M 4M 6M 8M 10M

1.2 Ratios

LIMN has a worse Return On Assets (-82.22%) than 71.04% of its industry peers.
Industry RankSector Rank
ROA -82.22%
ROE N/A
ROIC N/A
ROA(3y)13.49%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LIMN Yearly ROA, ROE, ROICLIMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LIMN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIMN Yearly Profit, Operating, Gross MarginsLIMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for LIMN has been reduced compared to 1 year ago.
Compared to 1 year ago, LIMN has a worse debt to assets ratio.
LIMN Yearly Shares OutstandingLIMN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M
LIMN Yearly Total Debt VS Total AssetsLIMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -6.07, we must say that LIMN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.07, LIMN is doing worse than 64.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.07
ROIC/WACCN/A
WACCN/A
LIMN Yearly LT Debt VS Equity VS FCFLIMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 0.05 indicates that LIMN may have some problems paying its short term obligations.
LIMN's Current ratio of 0.05 is on the low side compared to the rest of the industry. LIMN is outperformed by 97.84% of its industry peers.
LIMN has a Quick Ratio of 0.05. This is a bad value and indicates that LIMN is not financially healthy enough and could expect problems in meeting its short term obligations.
LIMN has a worse Quick ratio (0.05) than 97.84% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
LIMN Yearly Current Assets VS Current LiabilitesLIMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LIMN have decreased strongly by -288.31% in the last year.
EPS 1Y (TTM)-288.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LIMN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIMN Price Earnings VS Forward Price EarningsLIMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIMN Per share dataLIMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LIMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIMINATUS PHARMA INC-CL A

NASDAQ:LIMN (7/24/2025, 8:00:02 PM)

After market: 8.85 +0.38 (+4.49%)

8.47

+2 (+30.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap220.30M
AnalystsN/A
Price TargetN/A
Short Float %3.86%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS-0.55
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)13.49%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -6.07
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-288.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-126.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.78%
OCF growth 3YN/A
OCF growth 5YN/A